I

Incyte Corp

INCY

64.390
USD
-0.68
(-1.05%)
مغلق
حجم التداول
39,040
الربح لكل سهم
0
العائد الربحي
0
P/E
159
حجم السوق
12,574,725,183
أصول ذات صلة
AMGN
2.78
(0.84%)
335.22 USD
BMY
0.620
(1.30%)
48.180 USD
GILD
0.470
(0.62%)
76.510 USD
LLY
28.47
(3.54%)
832.74 USD
MRK
0.680
(0.60%)
113.800 USD
PFE
0.115
(0.38%)
30.650 USD
REGN
13.14
(1.22%)
1,091.19 USD
VRTX
9.75
(1.97%)
505.40 USD
الأخبار المقالات

العنوان: Incyte Corp

القطاع: Healthcare
الصناعة: Biotechnology
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.